Robert Bratzler, Ph.D. — Executive Chairman

Dr. Bratzler has been our Executive Chairman since March 2008. Previously, Dr. Bratzler was President and Chief Executive Officer of Coley Pharmaceutical Group from 1998 to the time of its sale to Pfizer in January 2008. A co-founder of Sepracor Inc., a research-based pharmaceutical company, in 1984, Dr. Bratzler also co-founded and helped build and finance several Sepracor group companies, including ChiRex, a pharmaceutical outsourcing company, where Dr. Bratzler served as President and Chief Executive Officer from 1996 to 1997. A former faculty member in the department of chemical engineering at Princeton University, Dr. Bratzler received his B.S. degree from the University of Michigan and his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

Lloyd Johnston, Ph.D. — Vice President Pharmaceutical Research and Development

Prior to joining Selecta Biosciences, Dr. Johnston was Vice President of Operations for Alkermes having responsibilities for process development, scale-up, and clinical manufacturing for pulmonary and sustained release injectable products as well as leadership of Alkermes 90,000 square foot manufacturing facility in Chelsea, MA. Dr. Johnston was also a project leader and member of Steering Committees for numerous products through various stages of development from Phase 1 through registration. Dr. Johnston was an original member of Advanced Inhalation Research (AIR®) Inc., a private company acquired by Alkermes in 1999. Prior to joining AIR, Lloyd was a professor in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.S. in Chemical Engineering from Queen's University in Canada, and his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Grayson Lipford, Ph.D. – Vice President Discovery

Prior to joining Selecta, Dr. Lipford was Vice President of Basic Research at Coley Pharmaceutical Group until Pfizer’s acquisition in early 2008. His responsibilities were for the identification, exploration and development through first in man studies for cutting edge treatments in immune modulation. He began his relationship with Coley as a research consultant in 1997. In 2001 he joined Coley GmbH, in Langenfeld Germany, and in 2003 moved to Coley Inc., in Wellesley, MA where he assisted in coordinating the international R&D effort. Prior to this, Grayson was a leading academic member of the Institute for Medical Microbiology and Immunology at the Technical University of Munich for 10 years, authoring more than 70 peer-reviewed articles, book chapters and many patents in the fields of antigen presentation and immune activation and suppression. Dr. Lipford received his B.S. in Biology and Chemistry from Virginia Commonwealth University and received his Ph.D. in Immunology from Eastern Virginia Medical School.